Why Did Aurobindo Pharma Limited (AUROPHARMA) Share Price Fall 5.09% Today?
Price Performance Summary
Key Reasons for Today's Fall
Aurobindo Pharma Limited (AUROPHARMA) shares fell 5.09% on 22 May 2026, closing at ₹1468.00. Today's news shows: Aurobindo Pharma Ltd stock (INE406A01037): rally to fresh 52-week high draws investor focus - AD HOC NEWS. Volume today was 30.4L shares, 1.0x the 30-day average — reflecting moderate participation. Sector performance data unavailable, with the stock outperforming its sector. Investors should monitor follow-up volume and any further news in coming sessions to confirm the trend.
Sector & Market Context
Aurobindo Pharma Limited operates in the Pharmaceuticals sector. Tracking sector peers and the broader index helps determine whether the move is company-specific or part of a wider trend.
Latest News on Aurobindo Pharma Limited
Showing news from last 48 hours
Aurobindo Pharma Ltd stock (INE406A01037): rally to fresh 52-week high draws investor focus - AD HOC NEWS
Aurobindo Pharma Ltd stock (INE406A01037): rally to fresh 52-week high draws investor focus AD HOC NEWS
Aurobindo Pharma Ltd up for third consecutive session - Business Standard
Aurobindo Pharma Ltd up for third consecutive session Business Standard
Frequently Asked Questions About Aurobindo Pharma Limited
Why did Aurobindo Pharma Limited share price fall today?
Aurobindo Pharma Limited (AUROPHARMA) fell 5.09% on 22 May 2026 due to Aurobindo Pharma Ltd stock (INE406A01037): rally to fresh 52-week high draws investor focus - AD HOC NEWS. Trading volume was 30.4L shares.
What is Aurobindo Pharma Limited's 52-week high and low?
52-week high/low data is not available for Aurobindo Pharma Limited at this time.
Is Aurobindo Pharma Limited a good stock to watch after today's move?
Today's 5.1% fall in AUROPHARMA on 30.4L volume is worth tracking. Investors should monitor follow-through price action and upcoming corporate announcements. This is not financial advice — please consult a SEBI-registered advisor before investing.
Disclaimer: NiftyPulse360 is not a SEBI-registered investment advisor. The information above is for educational purposes only and should not be construed as financial advice. Always consult a qualified advisor before making investment decisions.
💼 Expert View
Analyst ratings and broker views for Aurobindo Pharma Limitedare tracked across major brokerages including Motilal Oswal, ICICI Securities, and HDFC Securities. Investors should consider the consensus target price, upcoming earnings calendar, and any analyst upgrade/downgrade actions when evaluating today's decline. Compare with sector peers GLENMARK, SUNPHARMA, ZYDUSLIFE for relative strength analysis.
Note: NiftyPulse360 does not provide buy/sell recommendations. Consult a SEBI-registered investment advisor before making decisions.